Nanomedicine Market By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Implants, Others); By Modality (Diagnostics, Treatments); By Indication(Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Global nanomedicine market was valued at US$ 200.10 billion in 2020 and is expected to reach US$ 398.01 billion by 2029 growing at a CAGR of 10.45% over the forecast period. Today nanomedicine is rapidly being used to treat various diseases. Not only treatment, but nanomedicine is also used in diagnosis, monitoring and controlling the biological systems. The global nanomedicine market is making advancements owing to factors like emerging technologies for drug delivery, surging adoption rate of nanomedicine across different kind of applications, increased government support & funding, upward going demand for therapies that have lesser number of side effects and are cost efficient.
In the early stages of the COVID-19 pandemic, the anti-malaria drug known as hydroxychloroquine saw tremendous rise in the demand across the globe. This drug falls under the category of nanomedicine. Contrary to other industries, nanomedicine market was benefited by the pandemic.
Application
The nanomedicine market is segmented on the basis of application, modality and indication. Based on the type of application, the nanomedicine market is bifurcated into segments like drug delivery, vaccines, diagnostic imaging, regenerative medicine, implants and others. The product or the application segment accounts for largest share in the nanomedicine market because of the surging demands for this drugs which are highly effective in targeting cells or tissues in the body.
Modality
On the basis of modality, nanomedicine market is divided into diagnostics and treatment. At present, nanomedicines are being used as fluorescent market for purposes like screening and diagnostics. Meanwhile this drug is introducing latest therapeutic opportunities for a large number of agents that cannot be used effectively as traditional oral formulations owing to poor bioavailability.
Indication
On the basis of disease type, oncological diseases segment dominates the nanomedicine market and accounts for most of the revenue generated by it. On the other hand, the cardiovascular diseases segment is growing rapidly with the highest CAGR. The increasing number of patients suffering from cardiovascular diseases and extensive use of Nano-vectors, Nano-structured stents contributes to the growth of this segment.
Region
The North American nanomedicine market leads in terms of revenue generation owing to increased amount of investments in research in these kind of drugs from the US government affiliated market. The developed healthcare infrastructure and rising number of cancer patients also contribute to the growth of nanomedicine market in the region.
Nanomedicine Market Revenue & Forecast, (US$ Million), 2021 – 2029
Competitive Landscape
The report provides both, qualitative and quantitative research of nanomedicine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the nanomedicine market include Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company Inc., Nanosphere Inc., Pfizer Inc. and Teva Pharmaceuticals Industries Ltd amongst others.
Nanomedicine Market
- By Application
- Drug Delivery
- Vaccines
- Diagnostic Imaging
- Regenerative Medicine
- Implants
- Others
- By Modality
- Diagnostics
- Treatments
- By Indication
- Oncological Diseases
- Infectious Diseases
- Cardiovascular Diseases
- Orthopedic Disorders
- Neurological Diseases
- Urological Diseases
- Ophthalmological Diseases
- Immunological Diseases
- Others
- By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Nanomedicine Market
6.
Market
Synopsis: Nanomedicine Market
7.
Nanomedicine
Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Nanomedicine Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Nanomedicine Market
7.6. Industry Gross Margin Overview
7.7. Porter’s Five Force Analysis
7.8. Impact of Covid-19 on Nanomedicine Market
8.
Global
Nanomedicine Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Nanomedicine Market Revenue (US$ Mn)
8.2. Global Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
8.2.1. Drug Delivery
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market Forecast,
2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2020
8.2.1.5.1.2. Market Forecast, 2021 - 2029
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2020
8.2.1.5.2.2. Market Forecast, 2021 - 2029
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2020
8.2.1.5.3.2. Market Forecast, 2021 - 2029
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2020
8.2.1.5.4.2. Market Forecast, 2021 - 2029
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2020
8.2.1.5.5.2. Market Forecast, 2021 - 2029
8.2.2. Vaccines
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2020
8.2.2.5.1.2. Market Forecast, 2021 - 2029
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2020
8.2.2.5.2.2. Market Forecast, 2021 - 2029
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2020
8.2.2.5.3.2. Market Forecast, 2021 - 2029
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2020
8.2.2.5.4.2. Market Forecast, 2021 - 2029
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2020
8.2.2.5.5.2. Market Forecast, 2021 - 2029
8.2.3. Diagnostic Imaging
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2020
8.2.3.5.1.2. Market Forecast, 2021 - 2029
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2020
8.2.3.5.2.2. Market Forecast, 2021 - 2029
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2020
8.2.3.5.3.2. Market Forecast, 2021 - 2029
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2020
8.2.3.5.4.2. Market Forecast, 2021 - 2029
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2020
8.2.3.5.5.2. Market Forecast, 2021 - 2029
8.2.4. Regenerative Medicine
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2020
8.2.4.5.1.2. Market Forecast, 2021 - 2029
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2020
8.2.4.5.2.2. Market Forecast, 2021 - 2029
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2020
8.2.4.5.3.2. Market Forecast, 2021 - 2029
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2020
8.2.4.5.4.2. Market Forecast, 2021 - 2029
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2020
8.2.4.5.5.2. Market Forecast, 2021 - 2029
8.2.5. Implants
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.5.3.
Market
Forecast, 2021 - 2029
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1.
North
America
8.2.5.5.1.1. Market Estimation, 2015 - 2020
8.2.5.5.1.2. Market Forecast, 2021 - 2029
8.2.5.5.2.
Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2020
8.2.5.5.2.2. Market Forecast, 2021 - 2029
8.2.5.5.3.
Asia
Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2020
8.2.5.5.3.2. Market Forecast, 2021 - 2029
8.2.5.5.4.
Middle
East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2020
8.2.5.5.4.2. Market Forecast, 2021 - 2029
8.2.5.5.5.
Latin
America
8.2.5.5.5.1. Market Estimation, 2015 - 2020
8.2.5.5.5.2. Market Forecast, 2021 - 2029
8.2.6. Others
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.6.3.
Market
Forecast, 2021 - 2029
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1.
North
America
8.2.6.5.1.1. Market Estimation, 2015 - 2020
8.2.6.5.1.2. Market Forecast, 2021 - 2029
8.2.6.5.2.
Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2020
8.2.6.5.2.2. Market Forecast, 2021 - 2029
8.2.6.5.3.
Asia
Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2020
8.2.6.5.3.2. Market Forecast, 2021 - 2029
8.2.6.5.4.
Middle
East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2020
8.2.6.5.4.2. Market Forecast, 2021 - 2029
8.2.6.5.5.
Latin
America
8.2.6.5.5.1. Market Estimation, 2015 - 2020
8.2.6.5.5.2. Market Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Application
9.
Global
Nanomedicine Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
9.2.1. Diagnostics
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2020
9.2.1.5.1.2. Market Forecast, 2021 - 2029
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2020
9.2.1.5.2.2. Market Forecast, 2021 - 2029
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2020
9.2.1.5.3.2. Market Forecast, 2021 - 2029
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2020
9.2.1.5.4.2. Market Forecast, 2021 - 2029
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2020
9.2.1.5.5.2. Market Forecast, 2021 - 2029
9.2.2. Treatments
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2020
9.2.2.5.1.2. Market Forecast, 2021 - 2029
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2020
9.2.2.5.2.2. Market Forecast, 2021 - 2029
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2020
9.2.2.5.3.2. Market Forecast, 2021 - 2029
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2020
9.2.2.5.4.2. Market Forecast, 2021 - 2029
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2020
9.2.2.5.5.2. Market Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Modality
10. Global Nanomedicine Market Analysis and Forecasts,
2021 – 2029
10.1. Overview
10.2. Global Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
10.2.1. Oncological Diseases
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2020
10.2.1.5.1.2. Market Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2020
10.2.1.5.2.2. Market Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2020
10.2.1.5.3.2. Market Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2020
10.2.1.5.4.2. Market Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2020
10.2.1.5.5.2. Market Forecast, 2021 - 2029
10.2.2. Infectious Diseases
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2020
10.2.2.5.1.2. Market Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2020
10.2.2.5.2.2. Market Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2020
10.2.2.5.3.2. Market Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2020
10.2.2.5.4.2. Market Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2020
10.2.2.5.5.2. Market Forecast, 2021 - 2029
10.2.3. Cardiovascular Diseases
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2020
10.2.3.5.1.2. Market Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2020
10.2.3.5.2.2. Market Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2020
10.2.3.5.3.2. Market Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2020
10.2.3.5.4.2. Market Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2020
10.2.3.5.5.2. Market Forecast, 2021 - 2029
10.2.4. Orthopedic Disorders
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2020
10.2.4.5.1.2. Market Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2020
10.2.4.5.2.2. Market Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2020
10.2.4.5.3.2. Market Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2020
10.2.4.5.4.2. Market Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2020
10.2.4.5.5.2. Market Forecast, 2021 - 2029
10.2.5. Neurological Diseases
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 -
2020
10.2.5.3. Market Forecast, 2021 - 2029
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2020
10.2.5.5.1.2. Market Forecast, 2021 - 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2020
10.2.5.5.2.2. Market Forecast, 2021 - 2029
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2020
10.2.5.5.3.2. Market Forecast, 2021 - 2029
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2020
10.2.5.5.4.2. Market Forecast, 2021 - 2029
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2020
10.2.5.5.5.2. Market Forecast, 2021 - 2029
10.2.6. Urological Diseases
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 -
2020
10.2.6.3. Market Forecast, 2021 - 2029
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 - 2020
10.2.6.5.1.2. Market Forecast, 2021 - 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2020
10.2.6.5.2.2. Market Forecast, 2021 - 2029
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2020
10.2.6.5.3.2. Market Forecast, 2021 - 2029
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2020
10.2.6.5.4.2. Market Forecast, 2021 - 2029
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 - 2020
10.2.6.5.5.2. Market Forecast, 2021 - 2029
10.2.7. Ophthalmological Diseases
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 -
2020
10.2.7.3. Market Forecast, 2021 - 2029
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 - 2020
10.2.7.5.1.2. Market Forecast, 2021 - 2029
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2020
10.2.7.5.2.2. Market Forecast, 2021 - 2029
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2020
10.2.7.5.3.2. Market Forecast, 2021 - 2029
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2020
10.2.7.5.4.2. Market Forecast, 2021 - 2029
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 - 2020
10.2.7.5.5.2. Market Forecast, 2021 - 2029
10.2.8. Immunological Diseases
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2015 -
2020
10.2.8.3. Market Forecast, 2021 - 2029
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2015 - 2020
10.2.8.5.1.2. Market Forecast, 2021 - 2029
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2015 - 2020
10.2.8.5.2.2. Market Forecast, 2021 - 2029
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2015 - 2020
10.2.8.5.3.2. Market Forecast, 2021 - 2029
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 - 2020
10.2.8.5.4.2. Market Forecast, 2021 - 2029
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2015 - 2020
10.2.8.5.5.2. Market Forecast, 2021 - 2029
10.2.9. Others
10.2.9.1. Definition
10.2.9.2. Market Estimation and Penetration, 2015 -
2020
10.2.9.3. Market Forecast, 2021 - 2029
10.2.9.4. Compound Annual Growth Rate (CAGR)
10.2.9.5. Regional Bifurcation
10.2.9.5.1. North America
10.2.9.5.1.1. Market Estimation, 2015 - 2020
10.2.9.5.1.2. Market Forecast, 2021 - 2029
10.2.9.5.2. Europe
10.2.9.5.2.1. Market Estimation, 2015 - 2020
10.2.9.5.2.2. Market Forecast, 2021 - 2029
10.2.9.5.3. Asia Pacific
10.2.9.5.3.1. Market Estimation, 2015 - 2020
10.2.9.5.3.2. Market Forecast, 2021 - 2029
10.2.9.5.4. Middle East and Africa
10.2.9.5.4.1. Market Estimation, 2015 - 2020
10.2.9.5.4.2. Market Forecast, 2021 - 2029
10.2.9.5.5. Latin America
10.2.9.5.5.1. Market Estimation, 2015 - 2020
10.2.9.5.5.2. Market Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By Indication
11. North America Nanomedicine Market Analysis
and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America Nanomedicine Market Revenue
(US$ Mn)
11.2. North America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
11.2.1. Drug Delivery
11.2.2. Vaccines
11.2.3. Diagnostic Imaging
11.2.4. Regenerative Medicine
11.2.5. Implants
11.2.6. Others
11.3. North America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
11.3.1. Diagnostics
11.3.2. Treatments
11.4. North America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
11.4.1. Oncological Diseases
11.4.2. Infectious Diseases
11.4.3. Cardiovascular Diseases
11.4.4. Orthopedic Disorders
11.4.5. Neurological Diseases
11.4.6. Urological Diseases
11.4.7. Ophthalmological Diseases
11.4.8. Immunological Diseases
11.4.9. Others
11.5. North America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.1.1.1. Drug Delivery
11.5.1.1.2. Vaccines
11.5.1.1.3. Diagnostic Imaging
11.5.1.1.4. Regenerative Medicine
11.5.1.1.5. Implants
11.5.1.1.6. Others
11.5.1.2. U.S Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Modality
11.5.1.2.1. Diagnostics
11.5.1.2.2. Treatments
11.5.1.3. U.S Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Indication
11.5.1.3.1. Oncological Diseases
11.5.1.3.2. Infectious Diseases
11.5.1.3.3. Cardiovascular Diseases
11.5.1.3.4. Orthopedic Disorders
11.5.1.3.5. Neurological Diseases
11.5.1.3.6. Urological Diseases
11.5.1.3.7. Ophthalmological Diseases
11.5.1.3.8. Immunological Diseases
11.5.1.3.9. Others
11.5.2. Canada
11.5.2.1. Canada Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
11.5.2.1.1. Drug Delivery
11.5.2.1.2. Vaccines
11.5.2.1.3. Diagnostic Imaging
11.5.2.1.4. Regenerative Medicine
11.5.2.1.5. Implants
11.5.2.1.6. Others
11.5.2.2. Canada Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
11.5.2.2.1. Diagnostics
11.5.2.2.2. Treatments
11.5.2.3. Canada Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
11.5.2.3.1. Oncological Diseases
11.5.2.3.2. Infectious Diseases
11.5.2.3.3. Cardiovascular Diseases
11.5.2.3.4. Orthopedic Disorders
11.5.2.3.5. Neurological Diseases
11.5.2.3.6. Urological Diseases
11.5.2.3.7. Ophthalmological Diseases
11.5.2.3.8. Immunological Diseases
11.5.2.3.9. Others
11.5.3. Mexico
11.5.3.1. Mexico Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
11.5.3.1.1. Drug Delivery
11.5.3.1.2. Vaccines
11.5.3.1.3. Diagnostic Imaging
11.5.3.1.4. Regenerative Medicine
11.5.3.1.5. Implants
11.5.3.1.6. Others
11.5.3.2. Mexico Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
11.5.3.2.1. Diagnostics
11.5.3.2.2. Treatments
11.5.3.3. Mexico Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
11.5.3.3.1. Oncological Diseases
11.5.3.3.2. Infectious Diseases
11.5.3.3.3. Cardiovascular Diseases
11.5.3.3.4. Orthopedic Disorders
11.5.3.3.5. Neurological Diseases
11.5.3.3.6. Urological Diseases
11.5.3.3.7. Ophthalmological Diseases
11.5.3.3.8. Immunological Diseases
11.5.3.3.9. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Application
11.5.4.1.1. Drug Delivery
11.5.4.1.2. Vaccines
11.5.4.1.3. Diagnostic Imaging
11.5.4.1.4. Regenerative Medicine
11.5.4.1.5. Implants
11.5.4.1.6. Others
11.5.4.2. Rest of North America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Modality
11.5.4.2.1. Diagnostics
11.5.4.2.2. Treatments
11.5.4.3. Rest of North America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Indication
11.5.4.3.1. Oncological Diseases
11.5.4.3.2. Infectious Diseases
11.5.4.3.3. Cardiovascular Diseases
11.5.4.3.4. Orthopedic Disorders
11.5.4.3.5. Neurological Diseases
11.5.4.3.6. Urological Diseases
11.5.4.3.7. Ophthalmological Diseases
11.5.4.3.8. Immunological Diseases
11.5.4.3.9. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Application
11.6.3. By Modality
11.6.4. By Indication
12. Europe Nanomedicine Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe Nanomedicine Market Revenue (US$ Mn)
12.2. Europe Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.2.1. Drug Delivery
12.2.2. Vaccines
12.2.3. Diagnostic Imaging
12.2.4. Regenerative Medicine
12.2.5. Implants
12.2.6. Others
12.3. Europe Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.3.1. Diagnostics
12.3.2. Treatments
12.4. Europe Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.4.1. Oncological Diseases
12.4.2. Infectious Diseases
12.4.3. Cardiovascular Diseases
12.4.4. Orthopedic Disorders
12.4.5. Neurological Diseases
12.4.6. Urological Diseases
12.4.7. Ophthalmological Diseases
12.4.8. Immunological Diseases
12.4.9. Others
12.5. Europe Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Country
12.5.1. France
12.5.1.1. France Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.1.1.1. Drug Delivery
12.5.1.1.2. Vaccines
12.5.1.1.3. Diagnostic Imaging
12.5.1.1.4. Regenerative Medicine
12.5.1.1.5. Implants
12.5.1.1.6. Others
12.5.1.2. France Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.5.1.2.1. Diagnostics
12.5.1.2.2. Treatments
12.5.1.3. France Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.5.1.3.1. Oncological Diseases
12.5.1.3.2. Infectious Diseases
12.5.1.3.3. Cardiovascular Diseases
12.5.1.3.4. Orthopedic Disorders
12.5.1.3.5. Neurological Diseases
12.5.1.3.6. Urological Diseases
12.5.1.3.7. Ophthalmological Diseases
12.5.1.3.8. Immunological Diseases
12.5.1.3.9. Others
12.5.2. The UK
12.5.2.1. The UK Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.2.1.1. Drug Delivery
12.5.2.1.2. Vaccines
12.5.2.1.3. Diagnostic Imaging
12.5.2.1.4. Regenerative Medicine
12.5.2.1.5. Implants
12.5.2.1.6. Others
12.5.2.2. The UK Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.5.2.2.1. Diagnostics
12.5.2.2.2. Treatments
12.5.2.3. The UK Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.5.2.3.1. Oncological Diseases
12.5.2.3.2. Infectious Diseases
12.5.2.3.3. Cardiovascular Diseases
12.5.2.3.4. Orthopedic Disorders
12.5.2.3.5. Neurological Diseases
12.5.2.3.6. Urological Diseases
12.5.2.3.7. Ophthalmological Diseases
12.5.2.3.8. Immunological Diseases
12.5.2.3.9. Others
12.5.3. Spain
12.5.3.1. Spain Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.3.1.1. Drug Delivery
12.5.3.1.2. Vaccines
12.5.3.1.3. Diagnostic Imaging
12.5.3.1.4. Regenerative Medicine
12.5.3.1.5. Implants
12.5.3.1.6. Others
12.5.3.2. Spain Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.5.3.2.1. Diagnostics
12.5.3.2.2. Treatments
12.5.3.3. Spain Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.5.3.3.1. Oncological Diseases
12.5.3.3.2. Infectious Diseases
12.5.3.3.3. Cardiovascular Diseases
12.5.3.3.4. Orthopedic Disorders
12.5.3.3.5. Neurological Diseases
12.5.3.3.6. Urological Diseases
12.5.3.3.7. Ophthalmological Diseases
12.5.3.3.8. Immunological Diseases
12.5.3.3.9. Others
12.5.4. Germany
12.5.4.1. Germany Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.4.1.1. Drug Delivery
12.5.4.1.2. Vaccines
12.5.4.1.3. Diagnostic Imaging
12.5.4.1.4. Regenerative Medicine
12.5.4.1.5. Implants
12.5.4.1.6. Others
12.5.4.2. Germany Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.5.4.2.1. Diagnostics
12.5.4.2.2. Treatments
12.5.4.3. Germany Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.5.4.3.1. Oncological Diseases
12.5.4.3.2. Infectious Diseases
12.5.4.3.3. Cardiovascular Diseases
12.5.4.3.4. Orthopedic Disorders
12.5.4.3.5. Neurological Diseases
12.5.4.3.6. Urological Diseases
12.5.4.3.7. Ophthalmological Diseases
12.5.4.3.8. Immunological Diseases
12.5.4.3.9. Others
12.5.5. Italy
12.5.5.1. Italy Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.5.1.1. Drug Delivery
12.5.5.1.2. Vaccines
12.5.5.1.3. Diagnostic Imaging
12.5.5.1.4. Regenerative Medicine
12.5.5.1.5. Implants
12.5.5.1.6. Others
12.5.5.2. Italy Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
12.5.5.2.1. Diagnostics
12.5.5.2.2. Treatments
12.5.5.3. Italy Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
12.5.5.3.1. Oncological Diseases
12.5.5.3.2. Infectious Diseases
12.5.5.3.3. Cardiovascular Diseases
12.5.5.3.4. Orthopedic Disorders
12.5.5.3.5. Neurological Diseases
12.5.5.3.6. Urological Diseases
12.5.5.3.7. Ophthalmological Diseases
12.5.5.3.8. Immunological Diseases
12.5.5.3.9. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.6.1.1. Drug Delivery
12.5.6.1.2. Vaccines
12.5.6.1.3. Diagnostic Imaging
12.5.6.1.4. Regenerative Medicine
12.5.6.1.5. Implants
12.5.6.1.6. Others
12.5.6.2. Nordic Countries Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
12.5.6.2.1. Diagnostics
12.5.6.2.2. Treatments
12.5.6.3. Nordic Countries Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
12.5.6.3.1. Oncological Diseases
12.5.6.3.2. Infectious Diseases
12.5.6.3.3. Cardiovascular Diseases
12.5.6.3.4. Orthopedic Disorders
12.5.6.3.5. Neurological Diseases
12.5.6.3.6. Urological Diseases
12.5.6.3.7. Ophthalmological Diseases
12.5.6.3.8. Immunological Diseases
12.5.6.3.9. Others
12.5.6.4. Nordic Countries Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.7.1.1. Drug Delivery
12.5.7.1.2. Vaccines
12.5.7.1.3. Diagnostic Imaging
12.5.7.1.4. Regenerative Medicine
12.5.7.1.5. Implants
12.5.7.1.6. Others
12.5.7.2. Benelux Union Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
12.5.7.2.1. Diagnostics
12.5.7.2.2. Treatments
12.5.7.3. Benelux Union Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
12.5.7.3.1. Oncological Diseases
12.5.7.3.2. Infectious Diseases
12.5.7.3.3. Cardiovascular Diseases
12.5.7.3.4. Orthopedic Disorders
12.5.7.3.5. Neurological Diseases
12.5.7.3.6. Urological Diseases
12.5.7.3.7. Ophthalmological Diseases
12.5.7.3.8. Immunological Diseases
12.5.7.3.9. Others
12.5.7.4. Benelux Union Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.8.1.1. Drug Delivery
12.5.8.1.2. Vaccines
12.5.8.1.3. Diagnostic Imaging
12.5.8.1.4. Regenerative Medicine
12.5.8.1.5. Implants
12.5.8.1.6. Others
12.5.8.2. Rest of Europe Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
12.5.8.2.1. Diagnostics
12.5.8.2.2. Treatments
12.5.8.3. Rest of Europe Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
12.5.8.3.1. Oncological Diseases
12.5.8.3.2. Infectious Diseases
12.5.8.3.3. Cardiovascular Diseases
12.5.8.3.4. Orthopedic Disorders
12.5.8.3.5. Neurological Diseases
12.5.8.3.6. Urological Diseases
12.5.8.3.7. Ophthalmological Diseases
12.5.8.3.8. Immunological Diseases
12.5.8.3.9. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Application
12.6.3. By Modality
12.6.4. By Indication
13. Asia Pacific Nanomedicine Market Analysis
and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific Nanomedicine Market Revenue (US$
Mn)
13.2. Asia Pacific Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
13.2.1. Drug Delivery
13.2.2. Vaccines
13.2.3. Diagnostic Imaging
13.2.4. Regenerative Medicine
13.2.5. Implants
13.2.6. Others
13.3. Asia Pacific Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
13.3.1. Diagnostics
13.3.2. Treatments
13.4. Asia Pacific Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
13.4.1. Oncological Diseases
13.4.2. Infectious Diseases
13.4.3. Cardiovascular Diseases
13.4.4. Orthopedic Disorders
13.4.5. Neurological Diseases
13.4.6. Urological Diseases
13.4.7. Ophthalmological Diseases
13.4.8. Immunological Diseases
13.4.9. Others
13.5. Asia Pacific Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.1.1.1. Drug Delivery
13.5.1.1.2. Vaccines
13.5.1.1.3. Diagnostic Imaging
13.5.1.1.4. Regenerative Medicine
13.5.1.1.5. Implants
13.5.1.1.6. Others
13.5.1.2. China Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
13.5.1.2.1. Diagnostics
13.5.1.2.2. Treatments
13.5.1.3. China Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
13.5.1.3.1. Oncological Diseases
13.5.1.3.2. Infectious Diseases
13.5.1.3.3. Cardiovascular Diseases
13.5.1.3.4. Orthopedic Disorders
13.5.1.3.5. Neurological Diseases
13.5.1.3.6. Urological Diseases
13.5.1.3.7. Ophthalmological Diseases
13.5.1.3.8. Immunological Diseases
13.5.1.3.9. Others
13.5.2. Japan
13.5.2.1. Japan Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.2.1.1. Drug Delivery
13.5.2.1.2. Vaccines
13.5.2.1.3. Diagnostic Imaging
13.5.2.1.4. Regenerative Medicine
13.5.2.1.5. Implants
13.5.2.1.6. Others
13.5.2.2. Japan Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
13.5.2.2.1. Diagnostics
13.5.2.2.2. Treatments
13.5.2.3. Japan Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
13.5.2.3.1. Oncological Diseases
13.5.2.3.2. Infectious Diseases
13.5.2.3.3. Cardiovascular Diseases
13.5.2.3.4. Orthopedic Disorders
13.5.2.3.5. Neurological Diseases
13.5.2.3.6. Urological Diseases
13.5.2.3.7. Ophthalmological Diseases
13.5.2.3.8. Immunological Diseases
13.5.2.3.9. Others
13.5.3. India
13.5.3.1. India Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.3.1.1. Drug Delivery
13.5.3.1.2. Vaccines
13.5.3.1.3. Diagnostic Imaging
13.5.3.1.4. Regenerative Medicine
13.5.3.1.5. Implants
13.5.3.1.6. Others
13.5.3.2. India Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
13.5.3.2.1. Diagnostics
13.5.3.2.2. Treatments
13.5.3.3. India Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
13.5.3.3.1. Oncological Diseases
13.5.3.3.2. Infectious Diseases
13.5.3.3.3. Cardiovascular Diseases
13.5.3.3.4. Orthopedic Disorders
13.5.3.3.5. Neurological Diseases
13.5.3.3.6. Urological Diseases
13.5.3.3.7. Ophthalmological Diseases
13.5.3.3.8. Immunological Diseases
13.5.3.3.9. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
13.5.4.1.1. Drug Delivery
13.5.4.1.2. Vaccines
13.5.4.1.3. Diagnostic Imaging
13.5.4.1.4. Regenerative Medicine
13.5.4.1.5. Implants
13.5.4.1.6. Others
13.5.4.2. New Zealand Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
13.5.4.2.1. Diagnostics
13.5.4.2.2. Treatments
13.5.4.3. New Zealand Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
13.5.4.3.1. Oncological Diseases
13.5.4.3.2. Infectious Diseases
13.5.4.3.3. Cardiovascular Diseases
13.5.4.3.4. Orthopedic Disorders
13.5.4.3.5. Neurological Diseases
13.5.4.3.6. Urological Diseases
13.5.4.3.7. Ophthalmological Diseases
13.5.4.3.8. Immunological Diseases
13.5.4.3.9. Others
13.5.5. Australia
13.5.5.1. Australia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
13.5.5.1.1. Drug Delivery
13.5.5.1.2. Vaccines
13.5.5.1.3. Diagnostic Imaging
13.5.5.1.4. Regenerative Medicine
13.5.5.1.5. Implants
13.5.5.1.6. Others
13.5.5.2. Australia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
13.5.5.2.1. Diagnostics
13.5.5.2.2. Treatments
13.5.5.3. Australia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
13.5.5.3.1. Oncological Diseases
13.5.5.3.2. Infectious Diseases
13.5.5.3.3. Cardiovascular Diseases
13.5.5.3.4. Orthopedic Disorders
13.5.5.3.5. Neurological Diseases
13.5.5.3.6. Urological Diseases
13.5.5.3.7. Ophthalmological Diseases
13.5.5.3.8. Immunological Diseases
13.5.5.3.9. Others
13.5.6. South Korea
13.5.6.1. South Korea Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
13.5.6.1.1. Drug Delivery
13.5.6.1.2. Vaccines
13.5.6.1.3. Diagnostic Imaging
13.5.6.1.4. Regenerative Medicine
13.5.6.1.5. Implants
13.5.6.1.6. Others
13.5.6.2. South Korea Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
13.5.6.2.1. Diagnostics
13.5.6.2.2. Treatments
13.5.6.3. South Korea Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
13.5.6.3.1. Oncological Diseases
13.5.6.3.2. Infectious Diseases
13.5.6.3.3. Cardiovascular Diseases
13.5.6.3.4. Orthopedic Disorders
13.5.6.3.5. Neurological Diseases
13.5.6.3.6. Urological Diseases
13.5.6.3.7. Ophthalmological Diseases
13.5.6.3.8. Immunological Diseases
13.5.6.3.9. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.7.1.1. Drug Delivery
13.5.7.1.2. Vaccines
13.5.7.1.3. Diagnostic Imaging
13.5.7.1.4. Regenerative Medicine
13.5.7.1.5. Implants
13.5.7.1.6. Others
13.5.7.2. Southeast Asia Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
13.5.7.2.1. Diagnostics
13.5.7.2.2. Treatments
13.5.7.3. Southeast Asia Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
13.5.7.3.1. Oncological Diseases
13.5.7.3.2. Infectious Diseases
13.5.7.3.3. Cardiovascular Diseases
13.5.7.3.4. Orthopedic Disorders
13.5.7.3.5. Neurological Diseases
13.5.7.3.6. Urological Diseases
13.5.7.3.7. Ophthalmological Diseases
13.5.7.3.8. Immunological Diseases
13.5.7.3.9. Others
13.5.7.4. Southeast Asia Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Application
13.5.8.1.1. Drug Delivery
13.5.8.1.2. Vaccines
13.5.8.1.3. Diagnostic Imaging
13.5.8.1.4. Regenerative Medicine
13.5.8.1.5. Implants
13.5.8.1.6. Others
13.5.8.2. Rest of Asia Pacific Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Modality
13.5.8.2.1. Diagnostics
13.5.8.2.2. Treatments
13.5.8.3. Rest of Asia Pacific Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Indication
13.5.8.3.1. Oncological Diseases
13.5.8.3.2. Infectious Diseases
13.5.8.3.3. Cardiovascular Diseases
13.5.8.3.4. Orthopedic Disorders
13.5.8.3.5. Neurological Diseases
13.5.8.3.6. Urological Diseases
13.5.8.3.7. Ophthalmological Diseases
13.5.8.3.8. Immunological Diseases
13.5.8.3.9. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Application
13.6.3. By Modality
13.6.4. By Indication
14. Middle East and Africa Nanomedicine Market
Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa Nanomedicine Market
Revenue (US$ Mn)
14.2. Middle East and Africa Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Application
14.2.1. Drug Delivery
14.2.2. Vaccines
14.2.3. Diagnostic Imaging
14.2.4. Regenerative Medicine
14.2.5. Implants
14.2.6. Others
14.3. Middle East and Africa Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Modality
14.3.1. Diagnostics
14.3.2. Treatments
14.4. Middle East and Africa Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Indication
14.4.1. Oncological Diseases
14.4.2. Infectious Diseases
14.4.3. Cardiovascular Diseases
14.4.4. Orthopedic Disorders
14.4.5. Neurological Diseases
14.4.6. Urological Diseases
14.4.7. Ophthalmological Diseases
14.4.8. Immunological Diseases
14.4.9. Others
14.5. Middle East and Africa Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
14.5.1.1.1. Drug Delivery
14.5.1.1.2. Vaccines
14.5.1.1.3. Diagnostic Imaging
14.5.1.1.4. Regenerative Medicine
14.5.1.1.5. Implants
14.5.1.1.6. Others
14.5.1.2. Saudi Arabia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
14.5.1.2.1. Diagnostics
14.5.1.2.2. Treatments
14.5.1.3. Saudi Arabia Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
14.5.1.3.1. Oncological Diseases
14.5.1.3.2. Infectious Diseases
14.5.1.3.3. Cardiovascular Diseases
14.5.1.3.4. Orthopedic Disorders
14.5.1.3.5. Neurological Diseases
14.5.1.3.6. Urological Diseases
14.5.1.3.7. Ophthalmological Diseases
14.5.1.3.8. Immunological Diseases
14.5.1.3.9. Others
14.5.2. UAE
14.5.2.1. UAE Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.2.1.1. Drug Delivery
14.5.2.1.2. Vaccines
14.5.2.1.3. Diagnostic Imaging
14.5.2.1.4. Regenerative Medicine
14.5.2.1.5. Implants
14.5.2.1.6. Others
14.5.2.2. UAE Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Modality
14.5.2.2.1. Diagnostics
14.5.2.2.2. Treatments
14.5.2.3. UAE Nanomedicine Market Revenue (US$ Mn) and
Forecasts, By Indication
14.5.2.3.1. Oncological Diseases
14.5.2.3.2. Infectious Diseases
14.5.2.3.3. Cardiovascular Diseases
14.5.2.3.4. Orthopedic Disorders
14.5.2.3.5. Neurological Diseases
14.5.2.3.6. Urological Diseases
14.5.2.3.7. Ophthalmological Diseases
14.5.2.3.8. Immunological Diseases
14.5.2.3.9. Others
14.5.3. Egypt
14.5.3.1. Egypt Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
14.5.3.1.1. Drug Delivery
14.5.3.1.2. Vaccines
14.5.3.1.3. Diagnostic Imaging
14.5.3.1.4. Regenerative Medicine
14.5.3.1.5. Implants
14.5.3.1.6. Others
14.5.3.2. Egypt Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
14.5.3.2.1. Diagnostics
14.5.3.2.2. Treatments
14.5.3.3. Egypt Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
14.5.3.3.1. Oncological Diseases
14.5.3.3.2. Infectious Diseases
14.5.3.3.3. Cardiovascular Diseases
14.5.3.3.4. Orthopedic Disorders
14.5.3.3.5. Neurological Diseases
14.5.3.3.6. Urological Diseases
14.5.3.3.7. Ophthalmological Diseases
14.5.3.3.8. Immunological Diseases
14.5.3.3.9. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
14.5.4.1.1. Drug Delivery
14.5.4.1.2. Vaccines
14.5.4.1.3. Diagnostic Imaging
14.5.4.1.4. Regenerative Medicine
14.5.4.1.5. Implants
14.5.4.1.6. Others
14.5.4.2. Kuwait Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
14.5.4.2.1. Diagnostics
14.5.4.2.2. Treatments
14.5.4.3. Kuwait Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
14.5.4.3.1. Oncological Diseases
14.5.4.3.2. Infectious Diseases
14.5.4.3.3. Cardiovascular Diseases
14.5.4.3.4. Orthopedic Disorders
14.5.4.3.5. Neurological Diseases
14.5.4.3.6. Urological Diseases
14.5.4.3.7. Ophthalmological Diseases
14.5.4.3.8. Immunological Diseases
14.5.4.3.9. Others
14.5.5. South Africa
14.5.5.1. South Africa Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
14.5.5.1.1. Drug Delivery
14.5.5.1.2. Vaccines
14.5.5.1.3. Diagnostic Imaging
14.5.5.1.4. Regenerative
Medicine
14.5.5.1.5. Implants
14.5.5.1.6. Others
14.5.5.2. South Africa Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
14.5.5.2.1. Diagnostics
14.5.5.2.2. Treatments
14.5.5.3. South Africa Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
14.5.5.3.1. Oncological Diseases
14.5.5.3.2. Infectious Diseases
14.5.5.3.3. Cardiovascular Diseases
14.5.5.3.4. Orthopedic Disorders
14.5.5.3.5. Neurological Diseases
14.5.5.3.6. Urological Diseases
14.5.5.3.7. Ophthalmological Diseases
14.5.5.3.8. Immunological Diseases
14.5.5.3.9. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Nanomedicine
Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.1.1. Drug Delivery
14.5.6.1.2. Vaccines
14.5.6.1.3. Diagnostic Imaging
14.5.6.1.4. Regenerative Medicine
14.5.6.1.5. Implants
14.5.6.1.6. Others
14.5.6.2. Rest of Middle East & Africa Nanomedicine
Market Revenue (US$ Mn) and Forecasts, By Modality
14.5.6.2.1. Diagnostics
14.5.6.2.2. Treatments
14.5.6.3. Rest of Middle East & Africa Nanomedicine
Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.6.3.1. Oncological Diseases
14.5.6.3.2. Infectious Diseases
14.5.6.3.3. Cardiovascular Diseases
14.5.6.3.4. Orthopedic Disorders
14.5.6.3.5. Neurological Diseases
14.5.6.3.6. Urological Diseases
14.5.6.3.7. Ophthalmological Diseases
14.5.6.3.8. Immunological Diseases
14.5.6.3.9. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Application
14.6.3. By Modality
14.6.4. By Indication
15. Latin America Nanomedicine Market Analysis
and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America Nanomedicine Market Revenue
(US$ Mn)
15.2. Latin America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Application
15.2.1. Drug Delivery
15.2.2. Vaccines
15.2.3. Diagnostic Imaging
15.2.4. Regenerative Medicine
15.2.5. Implants
15.2.6. Others
15.3. Latin America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Modality
15.3.1. Diagnostics
15.3.2. Treatments
15.4. Latin America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Indication
15.4.1. Oncological Diseases
15.4.2. Infectious Diseases
15.4.3. Cardiovascular Diseases
15.4.4. Orthopedic Disorders
15.4.5. Neurological Diseases
15.4.6. Urological Diseases
15.4.7. Ophthalmological Diseases
15.4.8. Immunological Diseases
15.4.9. Others
15.5. Latin America Nanomedicine Market Revenue
(US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Application
15.5.1.1.1. Drug Delivery
15.5.1.1.2. Vaccines
15.5.1.1.3. Diagnostic Imaging
15.5.1.1.4. Regenerative Medicine
15.5.1.1.5. Implants
15.5.1.1.6. Others
15.5.1.2. Brazil Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Modality
15.5.1.2.1. Diagnostics
15.5.1.2.2. Treatments
15.5.1.3. Brazil Nanomedicine Market Revenue (US$ Mn)
and Forecasts, By Indication
15.5.1.3.1. Oncological Diseases
15.5.1.3.2. Infectious Diseases
15.5.1.3.3. Cardiovascular Diseases
15.5.1.3.4. Orthopedic Disorders
15.5.1.3.5. Neurological Diseases
15.5.1.3.6. Urological Diseases
15.5.1.3.7. Ophthalmological Diseases
15.5.1.3.8. Immunological Diseases
15.5.1.3.9. Others
15.5.2. Argentina
15.5.2.1. Argentina Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Application
15.5.2.1.1. Drug Delivery
15.5.2.1.2. Vaccines
15.5.2.1.3. Diagnostic Imaging
15.5.2.1.4. Regenerative Medicine
15.5.2.1.5. Implants
15.5.2.1.6. Others
15.5.2.2. Argentina Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Modality
15.5.2.2.1. Diagnostics
15.5.2.2.2. Treatments
15.5.2.3. Argentina Nanomedicine Market Revenue (US$
Mn) and Forecasts, By Indication
15.5.2.3.1. Oncological Diseases
15.5.2.3.2. Infectious Diseases
15.5.2.3.3. Cardiovascular Diseases
15.5.2.3.4. Orthopedic Disorders
15.5.2.3.5. Neurological Diseases
15.5.2.3.6. Urological Diseases
15.5.2.3.7. Ophthalmological Diseases
15.5.2.3.8. Immunological Diseases
15.5.2.3.9. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Application
15.5.3.1.1. Drug Delivery
15.5.3.1.2. Vaccines
15.5.3.1.3. Diagnostic Imaging
15.5.3.1.4. Regenerative Medicine
15.5.3.1.5. Implants
15.5.3.1.6. Others
15.5.3.2. Rest of Latin America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Modality
15.5.3.2.1. Diagnostics
15.5.3.2.2. Treatments
15.5.3.3. Rest of Latin America Nanomedicine Market
Revenue (US$ Mn) and Forecasts, By Indication
15.5.3.3.1. Oncological Diseases
15.5.3.3.2. Infectious Diseases
15.5.3.3.3. Cardiovascular Diseases
15.5.3.3.4. Orthopedic Disorders
15.5.3.3.5. Neurological Diseases
15.5.3.3.6. Urological Diseases
15.5.3.3.7. Ophthalmological Diseases
15.5.3.3.8. Immunological Diseases
15.5.3.3.9. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Application
15.6.3. By Modality
15.6.4. By Indication
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2020
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Abbott Laboratories
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. CombiMatrix Corporation
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. General Electric Company
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Sigma-Tau Pharmaceuticals, Inc.
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Johnson & Johnson
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Mallinckrodt plc.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Nanosphere, Inc
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Teva Pharmaceutical Industries Ltd
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Pfizer, Inc.
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Merck & Company, Inc.
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.